Artificial Intelligence (AI) Cytopathology Trial
Start Date
7/21/2021
Completion Date
1/30/2028
Summary
Purpose The primary objective of the study is to compare interpretation of EUS FNA/FNB samples for adequacy between ROSE and AI at bedside. To compare accuracy of preliminary diagnosis results between ROSE and AI at bedside versus final pathology report. Research design This is a prospective single center study to compare performance characteristics in the interpretation of EUS FNA/FNB samples between AI and ROSE. Procedures to be used Eligible patients will undergo EUS guided FNA/FNA of PSLs using standard of care. Sample slides are prepared by a cytopathologist at bedside and observed under a microscope. At the same time, the slides are scanned using a slide scanner and those images are saved for interpretation by AI at a later time.
Eligibility Criteria
Age Range: 18 years to 100 years
Interventions
Artificial Intelligence software ROSE
Conditions
Locations
Memorial Hermann Hospital
Houston, Texas 77030
United States